{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T01:55:35Z","timestamp":1777082135729,"version":"3.51.4"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>The risk of major bleeding complications in catheter directed thrombolysis (CDT) for acute limb ischemia (ALI) remains high, with reported major bleeding complication rates in up to 1 in every 10 treated patients. Fibrinogen was the only predictive marker used for bleeding complications in CDT, despite the lack of high quality evidence to support this. Therefore, recent international guidelines recommend against the use of fibrinogen during CDT. However, no alternative biomarkers exist to effectively predict CDT-related bleeding complications. The aim of the POCHET biobank is to prospectively assess the rate and etiology of bleeding complications during CDT and to provide a biobank of blood samples to investigate potential novel biomarkers to predict bleeding complications during CDT.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The POCHET biobank is a multicentre prospective biobank. After informed consent, all consecutive patients with lower extremity ALI eligible for CDT are included. All patients are treated according to a predefined standard operating procedure which is aligned in all participating centres. Baseline and follow-up data are collected. Prior to CDT and subsequently every six hours, venous blood samples are obtained and stored in the biobank for future analyses. The primary outcome is the occurrence of non-access related major bleeding complications, which is assessed by an independent adjudication committee. Secondary outcomes are non-major bleeding complications and other CDT related complications. Proposed biomarkers to be investigated include fibrinogen, to end the debate on its usefulness, anti-plasmin and D-Dimer.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Discussion and conclusion<\/jats:title>\n<jats:p>The POCHET biobank provides contemporary data and outcomes of patients during CDT for ALI, coupled with their blood samples taken prior and during CDT. Thereby, the POCHET biobank is a real world monitor on biomarkers during CDT, supporting a broad spectrum of future research for the identification of patients at high risk for bleeding complications during CDT and to identify new biomarkers to enhance safety in CDT treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0302830","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T17:30:22Z","timestamp":1715275822000},"page":"e0302830","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictors of bleeding complications during catHeter-dirEcted thrombolysis for peripheral arterial occlusions (POCHET)"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3714-5514","authenticated-orcid":true,"given":"Barend M.","family":"Mol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maarten C.","family":"Verwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Fijnheer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasper","family":"Florie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar A.","family":"Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falco","family":"Hietbrink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Nijkeuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evert-Jan P. A.","family":"Vonken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"van Weel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique P. V.","family":"de Kleijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1389-4141","authenticated-orcid":true,"given":"Gert J.","family":"de Borst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the POCHET study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"issue":"2","key":"pone.0302830.ref001","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejvs.2019.09.006","article-title":"Editor\u2019s Choice\u2013European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia.","volume":"59","author":"M Bj\u00f6rck","year":"2020","journal-title":"European Journal of Vascular and Endovascular Surgery."},{"key":"pone.0302830.ref002","article-title":"Recommended standards for reports dealing with lower extremity ischemia: Revised version","author":"RB Rutherford","year":"1997","journal-title":"J Vasc Surg"},{"key":"pone.0302830.ref003","first-page":"667","volume-title":"European Journal of Vascular and Endovascular Surgery","author":"HP Ebben","year":"2019"},{"key":"pone.0302830.ref004","article-title":"Long-Term Outcomes of Catheter-Directed Thrombolysis for Acute Lower Extremity Occlusions of Native Arteries and Prosthetic Bypass Grafts.","author":"AM Schrijver","year":"2016","journal-title":"Ann Vasc Surg"},{"issue":"4","key":"pone.0302830.ref005","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ejvs.2019.02.028","article-title":"Heterogeneity in Standard Operating Procedures for Catheter Directed Thrombolysis for Peripheral Arterial Occlusions in The Netherlands: A Nationwide Overview.","volume":"58","author":"BS Leenstra","year":"2019","journal-title":"European Journal of Vascular and Endovascular Surgery [Internet]."},{"key":"pone.0302830.ref006","article-title":"Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: The STILE trial","author":"RA Graor","year":"1994","journal-title":"In: Annals of Surgery"},{"issue":"16","key":"pone.0302830.ref007","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM199804163381603","article-title":"A Comparison of Recombinant Urokinase with Vascular Surgery as Initial Treatment for Acute Arterial Occlusion of the Legs.","volume":"338","author":"K Ouriel","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"pone.0302830.ref008","article-title":"Practice Trends of Fibrinogen Monitoring in Thrombolysis.","author":"C Kaufman","year":"2018","journal-title":"J Clin Med."},{"key":"pone.0302830.ref009","first-page":"1519","volume-title":"Journal of Vascular Surgery","author":"MHF Poorthuis","year":"2017"},{"key":"pone.0302830.ref010","volume-title":"Cochrane Database of Systematic Reviews","author":"I Robertson","year":"2013"},{"key":"pone.0302830.ref011","unstructured":"Clinical Trial Registry\u2014International Committee of Medical Journal Editors [Internet]. [cited 2024 Mar 12]. Available from: https:\/\/www.icmje.org\/recommendations\/browse\/publishing-and-editorial-issues\/clinical-trial-registration.html."},{"issue":"1","key":"pone.0302830.ref012","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.blre.2011.09.003","article-title":"Adverse events and safety issues in blood donation-A comprehensive review","volume":"26","author":"K Amrein","year":"2012","journal-title":"Blood Rev"},{"key":"pone.0302830.ref013","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-115-4-256","article-title":"Hemorrhagic Events during Therapy with Recombinant Tissue-Type Plasminogen Activator, Heparin, and Aspirin for Acute Myocardial Infarction Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial [Internet].","volume":"115","author":"EG Bovill","year":"1991","journal-title":"Annals of Internal Medicine"},{"issue":"23","key":"pone.0302830.ref014","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the bleeding academic research consortium","volume":"123","author":"R Mehran","year":"2011","journal-title":"Circulation"},{"issue":"11","key":"pone.0302830.ref015","first-page":"1083","article-title":"Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention. 1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation) Trial.","volume":"2","author":"G Montalescot","year":"2009","journal-title":"JACC Cardiovasc Interv."},{"key":"pone.0302830.ref016","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"on behalf of the subcommittee on control of anticoagulation of the Scientific and Standardization committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"pone.0302830.ref017","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The clavien-dindo classification of surgical complications: Five-year experience.","volume":"250","author":"PA Clavien","year":"2009","journal-title":"Annals of Surgery"},{"issue":"1","key":"pone.0302830.ref018","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"S Schulman","year":"2010","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"pone.0302830.ref019","first-page":"861","volume-title":"European Journal of Vascular and Endovascular Surgery","author":"B Leenstra","year":"2021"},{"issue":"3","key":"pone.0302830.ref020","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ejvs.2022.11.010","article-title":"Major Bleeding During Thrombolytic Therapy for Acute Lower Limb Ischaemia: Value of Laboratory Tests for Clinical Decision Making, 17 Years of Experience.","volume":"65","author":"SAN Doelare","year":"2023","journal-title":"European Journal of Vascular and Endovascular Surgery"},{"issue":"9","key":"pone.0302830.ref021","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/bjs.9579","article-title":"Outcome and complications after intra-arterial thrombolysis for lower limb ischaemia with or without continuous heparin infusion","volume":"101","author":"O Grip","year":"2014","journal-title":"British Journal of Surgery"},{"issue":"2","key":"pone.0302830.ref022","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11239-010-0520-2","article-title":"Risk factors for haemorrhage during local intra-arterial thrombolysis for lower limb ischaemia.","volume":"31","author":"M Kuoppala","year":"2011","journal-title":"J Thromb Thrombolysis."},{"issue":"12","key":"pone.0302830.ref023","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.113.006727","article-title":"Plasmin cleavage of von willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy","volume":"129","author":"C Tersteeg","year":"2014","journal-title":"Circulation"},{"key":"pone.0302830.ref024","author":"JE Sadler","journal-title":"Low von Willebrand factor: sometimes a risk factor and sometimes a disease [Internet]."},{"key":"pone.0302830.ref025","first-page":"1021","volume-title":"Circulation","author":"T Urano","year":"2017"},{"key":"pone.0302830.ref026","article-title":"Markers of coagulation and fibrinolysis predicting the outcome of acute ischemic stroke thrombolysis treatment: A review of the literature.","author":"Z Bagoly","year":"2019","journal-title":"Frontiers in Neurology"},{"key":"pone.0302830.ref027","article-title":"Lowering low-density lipoprotein particles in plasma using dextran sulphate co-precipitates procoagulant extracellular vesicles.","author":"JW Wang","year":"2018","journal-title":"Int J Mol Sci."},{"key":"pone.0302830.ref028","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00298","article-title":"Extracellular Vesicles Derived From Platelets, Red Blood Cells, and Monocyte-Like Cells Differ Regarding Their Ability to Induce Factor XII-Dependent Thrombin Generation.","volume":"8","author":"C Tripisciano","year":"2020","journal-title":"Front Cell Dev Biol."},{"key":"pone.0302830.ref029","author":"E Angl\u00e9s-Cano","journal-title":"Inhibition of Fibrinolysis by Lipoprotein(a)"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0302830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T17:30:46Z","timestamp":1715275846000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0302830"}},"subtitle":[],"editor":[{"given":"Ey\u00fcp Serhat","family":"\u00c7al\u0131k","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0302830","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}